tirzepatide compound banned What is the latest update on the Compounded ban FDA Drug Recalls and Warnings:

S., Dorairaj S

As Kailera prepares to advance KAI-9531 into a global clinical program, we look forward to evaluating both higher doses and longer duration of treatment to expand on KAI-9531s best-in-class potential, said Ron Renaud, President and Chief Executive Officer of Kailera

Type 1 patients interested in weight loss should consult an endocrinologist and PlexusDx medical team to explore safer alternatives or determine if low-dose GLP-1 therapy with intensive monitoring is appropriate

Data availability Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data